Review |
Corresponding author: Ashish Shah ( shah_ashishpharmacy@yahoo.co.in ) © 2022 Ashish Shah, Chhagan Patel.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Shah A, Patel C (2022) A concise review of inflammatory biomarkers targeted cancer therapy. Folia Medica 64(4): 572-580. https://doi.org/10.3897/folmed.64.e68365
|
Inflammation is considered a general protective reaction of localized tissue against injury, irritation, or swelling. Inflammation may be acute, which is part of the defensive response; or chronic, which may lead to the development of various diseases including cancer. Several pro-inflammatory genes play important role in the various cellular processes like cell proliferation, angiogenesis, metastasis, and suppression of apoptosis. These pro-inflammatory genes include TNF-α, interleukins, chemokines, MMPs, cyclooxygenase, lipoxygenase, iNOS, Jak/STAT pathway, etc. All these genes are mainly regulated by the transcription factor NF-κB, which is found active in many types of neoplastic cells. Therefore, developing molecules that target pro-inflammatory genes or transcription factor is believed to be one of the good strategies for development of anti-cancer agents. Literature data suggest that many anti-inflammatory agents, including non-steroidal anti-inflammatory drugs, corticosteroids, statins, metformin, embelin, and some natural products, can interfere with the tumor microenvironment by inhibiting pro-inflammatory genes or transcription factors and increasing cell apoptosis. This review describes the link between inflammation and cancer, the role of pro-inflammatory genes and transcription factors in the development of tumor cells, and the use of anti-inflammatory agents in cancer.
anti-inflammatory agents, cancer, cancer prevention, inflammation, inflammatory biomarkers
TNF : tumor necrosis factor;
COX : cyclooxygenase;
IL : interlukins;
MMPs : matrix metalloproteinases;
LOX : lipooxygenase;
iNOS : inducible nitric oxide synthase;
HIF : hypoxia inducible factor;
PI3K : phosphoinositide-3-Kinase;
MAPK : mitogen activated protein kinase;
PG: prostaglandin;
VEGF : vascular endothelial growth factor;
JAK : janus kinase;
STAT : signal transducer and activator of transcription protein;
PI3K : phosphoinositide-3-kinase;
SCC : squamous cell carcinoma;
NSAIDs : non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma;
CDK : cyclin-dependent kinases
In 1863, the first clue between inflammation and cancer was identified by Rudolf Ludwig Carl Virchow that the inflammatory process is one of the conditions for the development of cancer cells.[
Factors that increase the inflammation, types of inflammation and various receptors involved in inflammation, responsible for activation of tumor cells.
Prevention of cancer can be possible in two ways; the first is primary prevention by reducing exposure of risk factors of cancer and the second is by immunoprevention and chemoprevention. Immunoprevention aims to control the development (or initiation) of cancer cells by the immune system while the chemopreventive effect focused on suppressing or prevent the conversion of malignant to invasive cancer types. In this review we had discussed, the role of various inflammatory mediators involved in the promotion of tumor which gives an idea about the link between inflammation and cancer and the role of anti-inflammatory agents in the treatment of cancer.[
There are mainly two pathways that link inflammation and cancer: these are the intrinsic pathways and the extrinsic pathways. The first type of pathway is activated by inflammatory stimuli which increase the risk of cancer, and the second is due to genetic mutation which causes inflammation and cancer. This pathway is interconnected through various inflammatory mediators, which include various cytokines, growth factors, and metalloproteases (Table
Various inflammatory mediators involved in the promotion of different types of cancer[3,33]
Cancer type | Inflammatory receptor involved |
Breast cancer | CXCR4, CCR7, COX-2, MMP1, MM9 |
Cervical carcinoma | IL-1α, TNF, COX-1 |
Ovarian tumors | TNF, IL-8, CXCR4/CXCL12, CXCR4, SDF1, COX-2, iNOS |
Glioma | TNF, IL-8, COX-2 |
Prostate cancer | IL-8, CXCL14, COX-2 |
Melanoma | IL-8, IL-18, CXCR4, CCR7, CCR10, COX-2 |
Oesophageal adenocarcinoma | COX-2 |
Oesophageal SCC and AC | COX-2 |
Urinary bladder | COX-1, COX-2 |
Pancreatic carcinoma | IL-1α, IL-1β, MIP-3α, CCR6, COX-2 |
Head and neck SCC | COX-2 |
Lung carcinoma | IL-1α, IL-1β, COX-2, CXC, CXCL5, and CXCL8 |
Gastric carcinoma | IL-8, COX-2 |
Colorectal cancer | IL-6, COX-2 |
Brain tumors | 5-LOX |
Colon cancer | IL-6 COX-2, 5LOX, MMP7 |
Skin cancer | TNF, 5LOX, MMP9 |
Bladder cancer | IL-6 |
Renal cell carcinoma | IL-6, CCR3 |
Leukemia | TNF |
Various inflammatory targets that provide link between inflammation and cancer by involving in various stages of cancer cell development process.
TNF-alpha is a multicellular kinase that plays important role in various cellular events like cell differentiation, survival, and death. There are two types of this receptor; the first is TNFR1 that is expressed all over the cell and the second is TNFR2, which is expressed mainly in the immune cells. TNFR1 receptor contains the intracellular domain, the transmembrane domain, an extracellular domain, and it is considered as one of the important members of the death receptor family as it is mainly involved in the cell death program. Due to this, it is also considered a death domain (DD) receptor. TNFR2 does not contain the DD domain - its action mediates through TNFR1.[
Interleukins functioned like intercellular hormones that can alter cellular functions. There are several types of interleukins (IL) that include IL-1, IL-6, IL-8, and IL-18 which play an important role in cancer development. IL-1α promotes cervical carcinoma and also induces anchorage independence in embryo fibroblasts. IL-1β also increases the cancer cell growth and is mainly associated with the development of chemoresistance in pancreatic carcinoma.[
The chemokines family has four different members, which, based on the cysteine residues are classified as C, CC, CX3C, and CXC. Chemokines play either beneficial or non-beneficial role for cancer patients. Recruitment of mature dendritic and/or effectors cell provide beneficial effect while chemokine mediated recruitment of immature dendritic cell can increase tumor cell tolerance. In cancer cell development, chemokines play important role in the process like angiogenesis, inflammation, cell migration, etc.[
Matrix metalloproteins are involved in various biological processes like inflammation, wound healing, cellular migration, skeletal formation, and cancer. MMP9 upregulation is found in various stages of tumorigenesis. MMP9 transferred by bone marrow plays a crucial role in skin carcinogens; supported by the evidence that transgenic mice lacking MMP9 have reduced hyperproliferation and invasiveness.[
There are three isoforms of COX that have been identified: A) COX-1 is mainly involved in tissue homeostasis, platelet aggregation, renal blood flow, and maintenance of gastric mucosa, B) COX-2 is found in inflamed and neoplastic tissues, and C) COX-3 is mainly expressed in the brain and spinal cord. The COX pathway by PGH2 synthetase produces PGG2, which is unstable, and PGH2 in the presence of PGH2 synthase and peroxidase enzyme. This converts into various PGs and TxA2. COX-2 level in cancer can be elevated by cytokines, growth oncogene, and other factors. COX-2 is responsible for the development and growth of a variety of cancers.[
The metabolic process for conversion of arachidonic acid to leukotrienes requires the presence of a 5-lipoxygenase enzyme which is the key factor for this metabolic process. Leukotrienes play important role in some allergic and inflammatory conditions. Apart from that, they are also involved in the pathophysiological functions of the brain like cerebral ischemia, brain edema, and increase the permeability of the blood-brain barrier in brain tumors.[
Regulation of TNF, COX, LOX, and MMPs is done by the transcription factor NF-κB which is normally present in an inactivated state in most cells, but in cancer cells, NF-κB is found as active. The activation of NF-κB induces inflammation and tumorigenesis.[
Hypoxia-inducible factor contains two subunit alpha and beta; receptor present in the heterodimeric complex. The alpha subunit is less stable as compared to the beta subunit. Recent literature data have shown that inflammation (via inflammatory mediators) can also activate HIF-1 in normoxic conditions.[
There are three different enzymes required for the synthesis of nitric oxide and iNOS is one of them. Cytokines like IL-1β, TNF-α, and IFN-γ can stimulate this enzyme. The expression of iNOS is regulated by transcription factors including NF-kB, activator protein 1, signal transducer and activator of transcription, 1α interferon regulatory protein 1, nuclear factor interleukin-6, and high motility group I (γ) protein.[
STAT family includes seven members, which are involved in different cellular processes like survival, cell proliferation, and angiogenesis. Out of the seven members, the important member involved in cancer is the STAT3 transcription factor. The expression of STAT3 is stimulated mainly by IL6, IL-11, and other members of the cytokine family as well as growth factors. Upon activation, STAT3 phosphorylation followed by homodimerization occurs. This dimer shift into the nucleus binds with DNA and stimulates the transcription of some genes involved in oncogenic activation such as Bcl-2, CDK1, VEGF, etc. Due to this STAT3 is found highly expressed in several cancers like multiple myeloma, leukemia, prostate cancer, lymphoma, breast cancer, squamous cell carcinoma of the head and neck.[
The other pathways which are directly or indirectly activated by inflammation or inflammatory receptors include mitogen-activated protein kinase (MAPK), phosphoinositide-3-kinase (PI3K), CREB signaling pathway, and Wnt/beta-catenin pathway. MAPKs are involved in various cellular processes like cell growth, differentiation, survival, and various immune and stress-related responses.[
Targeting inflammatory pathways involved in tumor promotion can be a good strategy for the prevention of cancer, in this regard preventive and anti-cancer effects of anti-inflammatory drugs can be useful (Table
Preventive and anti-cancer effects of anti-inflammatory drugs in various types of cancer[39,46]
Drug | Preventive effect on cancer | Anti-cancer effect |
Aspirin | Bladder, breast, colorectal, oesophageal, and lung | Gastric and colon cancer |
Celecoxib | Bladder, breast, cervix, colorectal, lung, prostate | Prostate, liver and colon |
Ibuprofen | Colon adenoma | Breast cancer |
Sulindac | Breast cancer | Colon cancer |
Piroxicam | Colorectal cancer | Colon cancer |
Dexamethasone | Breast and rectal | Multiple myeloma |
The main role of NSAIDS as anticancer agents is due to their role of inhibition of COX1/2 enzyme which is required for the biosynthesis of prostaglandins and leukotrienes. The level of PGE2 is elevated in different types of cancer production. They increase cancer cell production by favoring angiogenesis, tumor growth, metastasis, and inhibiting apoptosis. PGE2 can activate several cellular pathways like MAPK, PI3K/AKT, and NF-kB which further activates VEGF, Bcl-2, EGFR, and MMPS and increase the rate of tumorigenesis. The possible mechanism for rational use of aspirin for cancer prevention involved inhibition of various targets like inhibition of COX1/2, certain pro-inflammatory cytokines, modulation on immune response, the effect on PI3K signaling, maintenance of cancer stem cell homeostasis, and decreased glycolytic rate in cancer cells.[
The investigation of the link between NSAIDs and cancer was done by Kune et al. The report suggests that patients taking NSAIDs had a significantly lower incidence of cancer. The positive results of NSAIDs in cancer prevention open a new direction in cancer research. The study was done on >1 million subjects with over 30 epidemiological studies; results suggest that NSAIDs can be prototypical agents in the prevention of cancer.[
Corticosteroids are used as anti-emetic agents to prevent nausea and vomiting driven by cancer chemotherapeutic agents. They are also effective as anti-inflammatory agents in various chronic inflammatory diseases. In the xenograft or experimental model of the breast, colorectal, glioma, and lung cancer. It was observed that pre-treatment with dexamethasone increases the effectiveness of chemotherapy. Dexamethasone was also found to decrease the incidence of lung tumors. The combination of dexamethasone with carfilzomib and lenalidomide had an advantageous effect in multiple myeloma patients.[
Statins are used as anti-hyperlipidemic agents, which are also reported for their anti-inflammatory properties. The mechanism involved in the anti-inflammatory activity is due to the reduction of the pro-inflammatory cytokine, macrophage infiltration, and C-reactive protein. Due to additional anti-inflammatory properties, statins can reduce the risk of several cancers which include colorectal cancer, HCC, and breast cancer.[
Some natural products and foods have anti-inflammatory effects – these include grapes (resveratrol), garlic, and curry powder (curcumin). These compounds have also shown anti-cancer properties due to the induction of apoptosis. These compounds have anti-inflammatory action due to inhibition of the target NF-κB, MAPK, JNK, VEGF, and COX and due to this, they have a role in the anticancer activity.[
Inflammation and inflammatory pathways play important roles in the development and progression of cancer. Inflammation provides the soil for the development of cancer seeds. Targeting inflammation is one of the good strategies for the prevention of cancer. Anti-inflammatory agents have been shown in experimental, clinical, and epidemiological studies. Currently, FDA-approved anti-inflammatory agents have limited use due to a lack of target specificity and toxicity. Changes in dose regimen or combination of an anti-inflammatory agent with other chemotherapeutic agents or development of new anti-inflammatory agents with target specificity and low side effects may provide the solution. The idea of targeting anti-inflammatory pathways to treat cancer is innovative, but at the same time, a better understanding of biochemical pathways and the development of anti-inflammatory agents with more target specificity with fewer side effects need to be more focused on new effective therapeutic strategies.